Active Filter(s):
Details:
Through the acquisition, Sun Pharma strengthen its anti-inflammatory portfolio by adding Disperzyme (bromelain), Disperzyme-CD and Phlogam from Aksigen Hospital Care.
Lead Product(s): Bromelain,Trypsin,Rutin
Therapeutic Area: Neurology Product Name: Disperzyme
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 30, 2023